Holen Sie sich die Stockscreener-App
8.14
0.49%
-0.10
Schlusskurs vom Vortag:
$8.24
Offen:
$8.24
24-Stunden-Volumen:
33,723
Relative Volume:
0.05
Marktkapitalisierung:
$515.42M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-27.03M
KGV:
-9.6905
EPS:
-0.84
Netto-Cashflow:
$-23.97M
1W Leistung:
-3.76%
1M Leistung:
+8.47%
6M Leistung:
+276.15%
1J Leistung:
+485.71%
1-Tages-Spanne:
$8.12
$8.40
1-Wochen-Bereich:
$7.78
$8.71
52-Wochen-Spanne:
$1.30
$10.00
Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile
Firmenname
Corvus Pharmaceuticals Inc
Sektor
Branche
Telefon
(650) 900-4520
Adresse
863 MITTEN ROAD, BURLINGAME, CA
Vergleichen Sie CRVS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| CRVS | 8.12 | 515.42M | 0 | -27.03M | -23.97M | -0.84 |
| VRTX | 447.53 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 741.03 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.31 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.73 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.47 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-08-18 | Eingeleitet | Oppenheimer | Outperform |
| 2021-12-01 | Fortgesetzt | Jefferies | Buy |
| 2021-05-27 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-02-10 | Herabstufung | Mizuho | Buy → Neutral |
| 2019-09-12 | Eingeleitet | Mizuho | Buy |
| 2019-05-29 | Eingeleitet | ROTH Capital | Buy |
| 2017-08-24 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2017-05-01 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2016-04-18 | Eingeleitet | Credit Suisse | Outperform |
| 2016-04-18 | Eingeleitet | Guggenheim | Buy |
Alle ansehen
Corvus Pharmaceuticals Inc Aktie (CRVS) Neueste Nachrichten
FY2024 EPS Estimates for CRVS Cut by Cantor Fitzgerald - MarketBeat
Corvus Pharmaceuticals (NASDAQ:CRVS) Sees Large Volume IncreaseWhat's Next? - MarketBeat
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q3 2024 Earnings Call Transcript - MSN
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Shares Sold by Towerview LLC - MarketBeat
Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis - The Manila Times
Corvus drug shows promise in systemic sclerosis models - Investing.com
Corvus' Soquelitinib Shows Promise in Preventing Systemic Sclerosis Lung Damage in Key Study | CRVS Stock News - StockTitan
Corvus Pharmaceuticals target raised to $13 by Jefferies - Investing.com UK
Corvus Pharmaceuticals: The Market Likes The Story (NASDAQ:CRVS) - Seeking Alpha
Earnings call: Corvus Pharmaceuticals reports Q3 financials and trial updates - Investing.com
Corvus Pharmaceuticals (NASDAQ:CRVS) Given New $14.00 Price Target at Oppenheimer - MarketBeat
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Gap Up Following Analyst Upgrade - MarketBeat
Corvus Pharmaceuticals Inc (CRVS) Q3 2024 Earnings Call Highlights: Strategic Advancements Amid ... By GuruFocus - Investing.com Canada
Corvus Pharmaceuticals Reports Q3 2024 Financial Results - TipRanks
Corvus: Q3 Earnings Snapshot - San Antonio Express-News
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results - The Manila Times
Corvus Pharma Reports $41.7M Cash Position, Advances Key Clinical Trials Despite Q3 Loss | CRVS Stock News - StockTitan
Corvus Pharmaceuticals (NASDAQ:CRVS) Hits New 1-Year HighHere's Why - MarketBeat
Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer - The Manila Times
Corvus' Ciforadenant Shows Promise in Prostate Cancer Treatment, Doubles Response Rate | CRVS Stock News - StockTitan
Palantir Technologies Inc Cl A (PLTR-N) QuotePress Release - The Globe and Mail
Corvus Pharmaceuticals (CRVS) Scheduled to Post Earnings on Tuesday - MarketBeat
Corvus Pharmaceuticals stock soars to 52-week high of $9.69 - Investing.com
Sunrun Inc (RUN-Q) QuotePress Release - The Globe and Mail
Microsoft Corp (MSFT-Q) QuotePress Release - The Globe and Mail
T-Cell Lymphoma Pipeline Insight Analysis Report 2024 - GlobeNewswire Inc.
Godaddy Inc (GDDY-N) QuotePress Release - The Globe and Mail
Enersys Inc (ENS-N) QuotePress Release - The Globe and Mail
Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2024 Financial Results on November 12, 2024 - WICZ
Corvus Pharmaceuticals (NASDAQ:CRVS) Reaches New 1-Year HighStill a Buy? - MarketBeat
Amer Superconductor (AMSC-Q) QuotePress Release - The Globe and Mail
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
Toll Brothers Inc (TOL-N) QuotePress Release - The Globe and Mail
Corvus Pharmaceuticals (NASDAQ:CRVS) Sees Unusually-High Trading VolumeStill a Buy? - MarketBeat
United Parcel Service (UPS-N) QuotePress Release - The Globe and Mail
S&P GSCI (GDF25) Quote - The Globe and Mail
Lumber Physical (LBU23) Quote - The Globe and Mail
Corvus Pharmaceuticals (NASDAQ:CRVS) Lowered to "Sell" Rating by StockNews.com - MarketBeat
Corvus Pharmaceuticals stock soars to 52-week high of $8.74 By Investing.com - Investing.com Canada
Corvus Pharmaceuticals stock soars to 52-week high of $8.74 - Investing.com
Corvus Pharmaceuticals (NASDAQ:CRVS) Hits New 12-Month HighHere's What Happened - MarketBeat
Where are the Opportunities in (CRVS) - Stock Traders Daily
Msc Industrial Direct Company (MSM-N) QuotePress Release - The Globe and Mail
Insiders Rewarded With US$3.9m Addition To Investment As Corvus Pharmaceuticals Stock Hits US$480m - Simply Wall St
Corvus Pharmaceuticals (NASDAQ:CRVS) Trading Up 6%Here's Why - MarketBeat
Corvus Pharmaceuticals (NASDAQ:CRVS) Stock Rating Upgraded by Mizuho - MarketBeat
Corvus Pharmaceuticals (NASDAQ:CRVS) Lifted to "Hold" at StockNews.com - MarketBeat
Corvus Pharmaceuticals secures new South San Francisco lease - Investing.com
Corvus Pharmaceuticals (NASDAQ:CRVS) Sets New 52-Week HighShould You Buy? - MarketBeat
Corvus Pharmaceuticals stock soars to 52-week high of $7.67 By Investing.com - Investing.com Australia
Corvus Pharmaceuticals stock soars to 52-week high of $7.67 - Investing.com India
Finanzdaten der Corvus Pharmaceuticals Inc-Aktie (CRVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.42%
0.16%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):